Serina Therapeutics, Inc.(SER)Earnings, Financials & Key RatiosSerina Therapeutics, Inc. (SER) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious cash position of $3.056 million against a $6.3 million quarterly operating loss suggests an imminent risk of further equity dilution to maintain operational continuity.
Serina Therapeutics, Inc. (SER) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for Serina Therapeutics, Inc. (SER)
HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology.
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy.
Key metrics vs top competitors for Serina Therapeutics, Inc. (SER)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.17 | $23.51M | -1.14 | -100% | — | -8145.22% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — | |
| $205.70 | $30.37B | 23.30 | 1.39% | 13.92% | 7.55% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — |
Serina Therapeutics, Inc. (SER) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Serina Therapeutics, Inc. (SER) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
Apr 21, 2026·SEC
Mar 25, 2026·SEC
Get notified when SER posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Serina Therapeutics, Inc. (SER) stock FAQ — growth, dividends, profitability & financials explained
Serina Therapeutics, Inc. (SER) reported $0.1M in revenue for fiscal year 2025. This represents a 92% decrease from $1.7M in 2016.
Serina Therapeutics, Inc. (SER) saw revenue decline by 100.0% over the past year.
Serina Therapeutics, Inc. (SER) reported a net loss of $21.3M for fiscal year 2025.
Serina Therapeutics, Inc. (SER) has a return on equity (ROE) of -8145.2%. Negative ROE indicates the company is unprofitable.
Serina Therapeutics, Inc. (SER) had negative free cash flow of $18.2M in fiscal year 2025, likely due to heavy capital investments.
